Document is current
Any future updates will be listed below
-
Authors
Waldron, Nick R. https://orcid.org/0009-0008-8507-3124
Silva, Diogo
Westaby, Daniel
Jiménez-Vacas, Juan
Taylor, Joe
Sharp, Adam https://orcid.org/0000-0002-3740-1612
-
Funding
Funding for this research was provided by:
Cancer Research UK
Wellcome Trust
Prostate Cancer Foundation
U.S. Department of Defense
National Institute for Health and Care Research
Prostate Cancer UK
US Department of Defense
- License Information
-
More Information
Article History
Received: 4 November 2025
Revised: 6 March 2026
Accepted: 30 March 2026
First Online: 13 May 2026
Competing interests
: AS is an employee of the Institute of Cancer Research, which has a commercial interest in abiraterone, PARP inhibition in DNA repair–defective cancers, and PI3K/AKT pathway inhibitors (no personal income). AS has received travel support from Sanofi, Roche/Genentech, and Nurix, and speaker honoraria from Astellas Pharma and Merck Sharp & Dohme. He has served as an advisor to AbbVie, DE Shaw Research, CHARM Therapeutics, Ellipses Pharma, and Droia Ventures. AS has been the Chief Investigator/Principal Investigator of industry-sponsored clinical trials. All other authors have no conflicts of interest.
